Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 17

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 17
---
” within the meaning of the federal securities laws. Our forward-looking statements include, but
are not limited to, statements about us and our industry, as well as statements regarding our or our management team’s expectations,
hopes, beliefs, intentions or strategies regarding the future. Additionally, any statements that refer to projections, forecasts or other
characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. We intend the
forward-looking statements to be covered by the safe harbor provisions of the federal securities laws. Words such as “may,”
“should,” “could,” “would,” “predicts,” “potential,” “continue,”
“expects,” “anticipates,” “future,” “intends,” “plans,” “believes,”
“estimates,” and similar expressions, as well as statements in future tense, may identify forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements should not be read as a
guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking
statements are based on information we have when those statements are made or management’s good faith belief as of that time with
respect to future events, and are subject to significant risks and uncertainties that could cause actual performance or results to differ
materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences
include, but are not limited to:

| ● | our projected financial position and estimated cash burn rate;                                                                                                                                                                                                        |
| ● | our estimates regarding expenses, future revenues, and capital requirements;                                                                                                                                                                                          |
| ● | the success, cost, and timing of our clinical trials;                                                                                                                                                                                                                 |
| ● | our ability to obtain funding for our operations necessary to complete further development and commercialization of our diagnostic tests or therapeutic product candidates;                                                                                           |
| ● | our dependence on third parties in the conduct of our clinical trials;                                                                                                                                                                                                |
| ● | our ability to obtain the necessary regulatory approvals to market and commercialize our diagnostic tests or therapeutic product candidates;                                                                                                                          |
| ● | the potential that the results of our pre-clinical and clinical trials indicate our current diagnostic tests or any future diagnostic tests or therapeutic product candidates we may seek to develop are unsafe or ineffective;                                       |
| ● | the results of market research conducted by us or others;                                                                                                                                                                                                             |
| ● | our ability to obtain and maintain intellectual property protection